Myomo Inc
MYO0.928USD
+0.027+3.05%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
35.69MMarket Cap
LossP/E TTM
More Details of Myomo Inc Company
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. The Company develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Myomo Inc Info
Ticker SymbolMYO
Company nameMyomo Inc
IPO dateJun 12, 2017
CEOGudonis (Paul R)
Number of employees184
Security typeOrdinary Share
Fiscal year-endJun 12
Address137 Portland Street
CityBOSTON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code02114
Phone16179969058
Websitehttps://myomo.com/
Ticker SymbolMYO
IPO dateJun 12, 2017
CEOGudonis (Paul R)
Company Executives of Myomo Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Paul R. Gudonis
Mr. Paul R. Gudonis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.25M
-0.79%
Mr. Thomas F. (Tom) Kirk, Ph.D.
Mr. Thomas F. (Tom) Kirk, Ph.D.
Lead Independent Director
Lead Independent Director
481.86K
+1.57%
Mr. David A. Henry
Mr. David A. Henry
Chief Financial Officer
Chief Financial Officer
427.90K
+11.59%
Dr. Harry Kovelman, M.D.
Dr. Harry Kovelman, M.D.
Chief Medical Officer
Chief Medical Officer
140.62K
+45.75%
Ms. Heather C. Getz, CPA
Ms. Heather C. Getz, CPA
Independent Director
Independent Director
41.75K
+246.97%
Dr. Milton M. Morris, Ph.D.
Dr. Milton M. Morris, Ph.D.
Independent Director
Independent Director
--
--
Mr. Thomas A. Crowley, Jr.
Mr. Thomas A. Crowley, Jr.
Independent Director
Independent Director
--
--
Mr. Micah J. Mitchell
Mr. Micah J. Mitchell
Chief Commercial Officer
Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Paul R. Gudonis
Mr. Paul R. Gudonis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.25M
-0.79%
Mr. Thomas F. (Tom) Kirk, Ph.D.
Mr. Thomas F. (Tom) Kirk, Ph.D.
Lead Independent Director
Lead Independent Director
481.86K
+1.57%
Mr. David A. Henry
Mr. David A. Henry
Chief Financial Officer
Chief Financial Officer
427.90K
+11.59%
Dr. Harry Kovelman, M.D.
Dr. Harry Kovelman, M.D.
Chief Medical Officer
Chief Medical Officer
140.62K
+45.75%
Ms. Heather C. Getz, CPA
Ms. Heather C. Getz, CPA
Independent Director
Independent Director
41.75K
+246.97%
Dr. Milton M. Morris, Ph.D.
Dr. Milton M. Morris, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
Direct to patient
7.42M
76.88%
Clinical/Medical providers
2.23M
23.12%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Direct to patient
7.42M
76.88%
Clinical/Medical providers
2.23M
23.12%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.86%
Herr Investment Group LLC
7.40%
Triple Gate Capital, LP
7.35%
BlackRock Institutional Trust Company, N.A.
3.89%
The Vanguard Group, Inc.
3.86%
Other
67.63%
Shareholders
Shareholders
Proportion
Rosalind Advisors, Inc.
9.86%
Herr Investment Group LLC
7.40%
Triple Gate Capital, LP
7.35%
BlackRock Institutional Trust Company, N.A.
3.89%
The Vanguard Group, Inc.
3.86%
Other
67.63%
Shareholder Types
Shareholders
Proportion
Hedge Fund
21.84%
Investment Advisor
18.48%
Individual Investor
7.33%
Investment Advisor/Hedge Fund
6.34%
Research Firm
3.44%
Pension Fund
0.12%
Bank and Trust
0.08%
Other
42.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
153
21.95M
58.07%
-1.84M
2025Q2
131
25.59M
71.13%
+1.42M
2025Q1
128
23.88M
66.62%
+977.96K
2024Q4
112
23.29M
69.71%
+5.81M
2024Q3
85
19.54M
71.85%
+1.13M
2024Q2
79
18.43M
69.76%
+448.58K
2024Q1
77
16.43M
64.97%
-1.27M
2023Q4
72
14.80M
62.04%
-346.58K
2023Q3
64
15.22M
79.76%
+6.49M
2023Q2
62
8.10M
62.40%
+2.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosalind Advisors, Inc.
3.60M
9.51%
+892.13K
+33.00%
Jun 30, 2025
Herr Investment Group LLC
2.85M
7.53%
+1.20M
+72.93%
Jun 30, 2024
Triple Gate Capital, LP
2.83M
7.47%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.51M
4%
+1.40M
+1213.08%
Jun 30, 2025
The Vanguard Group, Inc.
1.49M
3.94%
+226.35K
+17.94%
Jun 30, 2025
Gudonis (Paul R)
1.25M
3.3%
-10.00K
-0.79%
Sep 09, 2025
Goldman Sachs & Company, Inc.
367.08K
0.97%
+201.64K
+121.88%
Jun 30, 2025
Geode Capital Management, L.L.C.
669.28K
1.77%
+412.63K
+160.78%
Jun 30, 2025
Renaissance Technologies LLC
541.40K
1.43%
+448.11K
+480.28%
Jun 30, 2025
Soleus Capital Management, L.P.
704.27K
1.86%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Myomo Inc?
The top five shareholders of Myomo Inc are:
Rosalind Advisors, Inc. holds 3.60M shares, accounting for 9.51% of the total shares.
Herr Investment Group LLC holds 2.85M shares, accounting for 7.53% of the total shares.
Triple Gate Capital, LP holds 2.83M shares, accounting for 7.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.51M shares, accounting for 4.00% of the total shares.
The Vanguard Group, Inc. holds 1.49M shares, accounting for 3.94% of the total shares.
Rosalind Advisors, Inc. holds 3.60M shares, accounting for 9.51% of the total shares.
Herr Investment Group LLC holds 2.85M shares, accounting for 7.53% of the total shares.
Triple Gate Capital, LP holds 2.83M shares, accounting for 7.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 1.51M shares, accounting for 4.00% of the total shares.
The Vanguard Group, Inc. holds 1.49M shares, accounting for 3.94% of the total shares.
What are the top three shareholder types of Myomo Inc?
The top three shareholder types of Myomo Inc are:
Rosalind Advisors, Inc.
Herr Investment Group LLC
Triple Gate Capital, LP
Rosalind Advisors, Inc.
Herr Investment Group LLC
Triple Gate Capital, LP
How many institutions hold shares of Myomo Inc (MYO)?
As of 2025Q3, 153 institutions hold shares of Myomo Inc, with a combined market value of approximately 21.95M, accounting for 58.07% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.06%.
What is the biggest source of revenue for Myomo Inc?
In FY2025Q2, the Direct to patient business generated the highest revenue for Myomo Inc, amounting to 7.42M and accounting for 76.88% of total revenue.
